Rhythm Pharmaceuticals Valuation Multiples

Rhythm Pharmaceuticals Overview

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

Founded

2008

HQ

Employees

283

Website

rhythmtx.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $222M

EBITDA: ($194M)

EV

$6B

Valuation Multiples

Multiples.vc

Start free trial

Rhythm Pharmaceuticals Financials

Rhythm Pharmaceuticals reported last 12-month revenue of $222M and negative EBITDA of ($194M).

In the same LTM period, Rhythm Pharmaceuticals generated $199M in gross profit, ($194M) in EBITDA losses, and had net loss of ($203M).

Rhythm Pharmaceuticals P&L

In the most recent fiscal year, Rhythm Pharmaceuticals reported revenue of $195M and EBITDA of ($174M).

Rhythm Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX

Rhythm Pharmaceuticals Stock Performance

Rhythm Pharmaceuticals has current market cap of $6B, and enterprise value of $6B.

Rhythm Pharmaceuticals' stock price is $88.69.

Rhythm Pharmaceuticals Valuation Multiples

Rhythm Pharmaceuticals trades at 26.1x EV/Revenue multiple, and (29.8x) EV/EBITDA.

Rhythm Pharmaceuticals Financial Valuation Multiples

As of April 18, 2026, Rhythm Pharmaceuticals has market cap of $6B and EV of $6B.

Equity research analysts estimate Rhythm Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Rhythm Pharmaceuticals has a P/E ratio of (29.8x).

Rhythm Pharmaceuticals Margins & Growth Rates

Rhythm Pharmaceuticals' revenue in the last 12 month grew by 62%.

Rhythm Pharmaceuticals' revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $1.3M for the same period.

Rhythm Pharmaceuticals' rule of 40 is (20%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Rhythm Pharmaceuticals' rule of X is 57% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Rhythm Pharmaceuticals Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Rhythm Pharmaceuticals M&A Activity

Rhythm Pharmaceuticals acquired XXX companies to date.

Last acquisition by Rhythm Pharmaceuticals was on XXXXXXXX, XXXXX. Rhythm Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Rhythm Pharmaceuticals Investment Activity

Rhythm Pharmaceuticals invested in XXX companies to date.

Rhythm Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Rhythm Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).